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Introduction. Fatigue is a common symptom, but only a few eﬀective treatments are available. This study was conducted to assess
the eﬃcacy and safety of the human placental extract solution, which has been known to have a fatigue recovery eﬀect. Methods.
A total of 315 subjects were randomly assigned to three groups: group 1 (with Unicenta solution administration), group 2 (with
exclusively human placental extract administration, excluding other ingredients from the Unicenta solution), and the placebo
group. Subsequently, solutions were administered for four weeks. Results. The fatigue recovery rate was 71.00% in group 1, 71.72%
in group 2, and 44.21% in the placebo group, which show statistically signiﬁcant diﬀerences between the group 1 and the placebo
group(P value = 0.0002), andbetween group2 and theplacebo group(P value = 0.0001). Conclusion. Thehuman placental extract
solution was eﬀective in the improvement of fatigue.
1.Introduction
The placenta is an organ that stores many active molecules
such as various nutrients and immune chemicals that are
required for life sustenance and proliferation of fetus.
Human placental extract (HPE) has been known to have
many ingredients with biological activity and various curing
eﬀects. So far, molecules, such as hormones, proteins, lipids,
nucleicacids,glycosaminoglycan,aminoacids,vitamins,and
minerals, have been extracted and identiﬁed from HPE [1–
3]. In addition to a Japanese study that reported that the
placenta extract was eﬀective in recovery from fatigue and
in ergogenic aid by increasing the blood ﬂow to facilitate
nutrition supply and promote excretion of accumulated
body waste [4], several studies on antioxidation [2], anti-
inﬂammation [4], and the whitening function [5, 6]h a v e
been conducted. Most of these studies, however, had a
restriction in that they were conducted on animals or were
not comprehensive.
The history of use of the placenta as a curing agent is very
old. Hippocrates in Greece used the placenta for treatments,
and medical information on the placenta was included in
many Chinese medical books.
In modern medicine, Dr. Filatov of the Soviet Union ﬁrst
used the placenta to treat diseases in the 1930s. In Japan,
treatments using the human placenta began in the 1950s,
with indications of improvement of the hepatic function and
menopausal disorder.
In South Korea, the placenta has been used in skin care
and for recovery from fatigue or allergy in many clinics. The
eﬃcacy of the placenta has not yet been scientiﬁcally veriﬁed,
though. Furthermore, its pharmaceutical mechanism and
adverse events have not been fully studied yet.2 Evidence-Based Complementary and Alternative Medicine
Although chronic fatigue is a common symptom in the
primary medical care system, its causes are not clear in many
cases, and eﬀective treatment methods have not been well
established.
In this study, a multicenter, double-blind, randomized
experiment was conducted using human placental extracts
solution(Unicenta), which has been approved as having the
eﬀects of fatigue recovery and ergogenic aid, to evaluate the
eﬃcacy of the placenta on fatigue via score changes in the
checklist of individual strength (CIS). In addition, the safety
of the placenta was investigated by analyzing adverse events,
vital signs, and laboratory test results.
2.MaterialsandMethods
2.1. Study Design. Of the patients who visited one of six
medical centers in Korea from September 10, 2008 to March
12, 2009, those who had persistent fatigue for one month or
more were selected as the subjects of this study.
The subject inclusion and exclusion criteria were as
follows.
2.1.1. Inclusion Criteria.
(1) Age: 18–75 years,
(2) persistent fatigue for one month or higher upon
screening,
(3) fatigue neither from organopathy nor continued
exercise,
(4) total CIS score ≥ 76 points upon screening,
(5) HospitalAnxiety andDepressionScale(HADS)score
≤ 10 points upon screening.
2.1.2. Exclusion Criteria.
(1) Previous record of alcohol or drug abuse,
(2) hepatic and renal dysfunction (two times more than
the normal upper limit in any of the followings: AST,
ALT, total bilirubin, and blood creatinine),
(3) chronic viral hepatitis B or C,
(4) if the following underlying diseases were identi-
ﬁed: uncontrolled hypertension (≥170/110mmHg),
diabetes, malignant tumor, tuberculosis, asthma,
glaucoma, multiple sclerosis, hypothyroidism, major
depressive disorder, bipolar disorder, schizophre-
nia, delusional disorder, dementia, bulimia nervosa,
severe obesity (≥45BMI), fatty liver, hepatitis due
to medication/alcohol, liver cirrhosis, chronic renal
failure, patient on dialysis, phenylketonuria,
(5) investigators adjudged the diﬃculty of the patient’s
participation due to severe metabolic diseases, car-
diovascular/cerebrovascular diseases, systemic infec-
tious diseases, and gastrointestinal diseases that may
cause physical and mental fatigue,
(6) pregnancy, breast feeding, or women of childbearing
age without a suitable contraceptive,
(7) previous record of hypersensitivity to HPE or other
animal derivatives,
(8) exercise therapy or chemotherapy that should not
be used in combination with study medication is
expected to be conducted during the study period,
(9) anti-HIV positive,
(10) use of testosterone.
Of the 347 applicants who underwent the screening pro-
cess, 32 subjects were excluded (not eligible for inclu-
sion/exclusion criteria: 23, withdrawal of informed consent:
8, follow-up lost: 1). A total of 315 subjects were randomly
assigned to three groups: Group 1 (with Unicenta solution
administration), group 2 (with exclusively human placental
extracts and excluding other ingredients from the Unicenta
solution), and the placebo group. As the Unicenta solution
includes other components (thiamin nitric acid, riboﬂavin
sodium phosphate, pyridoxine hydrochloric acid, nicoti-
namide, and caﬀeine anhydrous) that have a fatigue recovery
eﬀect besides the human placental extract, the experimental
groups were divided into two groups to assess the eﬃcacy of
the human placental extract by excluding other components
that may aﬀect fatigue recovery.
Of the 315 subjects, 294 subjects completed this study,
as 16 subjects were withdrawn due to their violation of the
inclusion/exclusioncriteriaandﬁvesubjectsdidnotundergo
eﬃcacy assessment. The subjects were instructed not to take
other medications that may cause fatigue during the study
period.
All the subjects completed an informed consent form
before participating in the study, and the study was con-
ducted after the approval of the Institutional Review Board
(IRB) of every participated medical centers.
2.2. Methods. After the subjects’ completion of an informed
consent form, their medical records, laboratory test results,
and CIS [7] and HADS score [8] were reviewed, and their
serious life events were assessed. The subjects took the
assigned solutions once everyday for four weeks. On the
second week of the study period their physical condition,
vital signs, fatigue, serious life events, and adverse events
were checked. Their laboratory test results, pregnancy test
results, fatigue, serious life events, and adverse events were
checked after the completion of the four-week study period.
The subjects who had adverse events were checked again on
the sixth week of the study period (Table 1).
The subjects’ improvement of fatigue was checked via
CIS [7]. The questionnaire had 20 items, and a maximum of
7p o i n t sw a sg i v e nt oe a c hi t e m .H i g h e rt o t a ls c o r e sr e ﬂ e c t e d
a higher degree of fatigue. In this study, the criterion of the
CIS score for the subject selection was 76 points.
2.3. Statistical Analysis. SPSS for Windows Version 15.0
(SPSSInc.,USA)wasusedforthestatisticalanalysis.Thechi-
square test or Fisher’s exact test was conducted to investigate
the diﬀerence in the frequency of the subjects who had
improved CIS scores of less than 76 points which was found
among the subject groups. In addition, the unpaired t-testEvidence-Based Complementary and Alternative Medicine 3
Table 1: Schedule of the clinical trials.
Screening Treatment Follow-up3
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5
−2w e e k s 1d a y 2w e e k s 4w e e k s 6w e e k s
Laboratory test1     
Electrocardiogram    
Pregnancy test2   
Physical examination & Vital signs         
HADS  
CIS         
Assessment of serious life events         
Random assignment  
Adverse event     
1Items of the laboratory test
(i) Blood test: CBC, ESR.
(ii)Serumbiochemicalassay:Glucose,BUN,Creatinine,Totalprotein,Albumin,Totalbilirubin,AST,ALT,ALP,Totalcholesterol,triglyceride,LDL-C,HDL-C.
(iii) Urine test: Protein, Glucose, Blood, WBC, pH.
2Conducted only on fertile women.
3Conducted only if adverse events were identiﬁed.
Table 2: Demographic information and characteristics of the subjects.
Demographic information Group 1 Group 2 Placebo group P value
N = 101 N = 102 N = 96
Sex Male n (%) 13 (12.87) 22 (21.57) 13 (13.54) 0.1729†
Female n (%) 88 (87.13) 80 (78.43) 83 (86.46)
Fertility No n (%) 24 (27.27) 16 (20.00) 16 (19.28) 0.3796†
Yes n (%) 64 (72.73) 64 (80.00) 67 (80.72)
Age
Age (years) Mean ± SD 41.20 ± 10.89 40.53 ± 11.23 39.97 ± 11.94 0.7486$
18–29 years n (%) 14 (13.86) 15 (14.71) 21 (21.88) 0.5497†
30–39 years n (%) 30 (29.70) 41 (40.20) 30 (31.25)
40–49 years n (%) 33 (32.67) 25 (24.51) 24 (25.00)
50–59 years n (%) 19 (18.81) 14 (13.73) 15 (15.63)
60–75 years n (%) 5 (4.95) 7 (6.86) 6 (6.25)
Anxiety (HADS) Mean ± SD 6.75 ± 2.59 5.81 ± 2.36 5.97 ± 2.55 0.0178$
Depression (HADS) Mean ± SD 6.74 ± 2.43 6.60 ± 2.41 6.69 ± 2.40 0.9114$
Height (cm) Mean ± SD 159.70 ± 6.50 161.20 ± 6.79 161.30 ± 7.10 0.1759$
Weight (kg) Mean ± SD 57.09 ± 9.19 57.73 ± 9.02 58.55 ± 9.54 0.5410$
Heart rate (beat/minute) Mean ± SD 73.94 ± 8.39 74.67 ± 8.76 74.69 ± 8.18 0.7759$
Systolic BP (mmHg) Mean ± SD 117.64 ± 13.64 115.44 ± 12.46 119.10 ± 13.26 0.1424$
Diastolic BP (mmHg) Mean ± SD 74.33 ± 9.81 72.78 ± 8.78 75.07 ± 9.46 0.2135$
Alcohol No n (%) 81 (80.20) 83 (81.37) 77 (80.21) 0.9710†
consumption Yes n (%) 20 (19.80) 19 (18.63) 19 (19.79)
Serious life No n (%) 98 (97.03) 95 (93.14) 94 (97.92) 0.2544‡
events Yes n (%) 3 (2.97) 7 (6.86) 2 (2.08)
$ANOVA, †Chi-square test, ‡Fisher’s exact test.
Table 3: Fatigue recovery rate of the CIS score.
Fatigue recovery rate Group 1 Group 2 Placebo P value1 P value2
(N = 100) (N = 99) (N = 95)
Visit 3 n (%) 51 (51.00) 58 (58.59) 44 (46.32) 0.5130† 0.0871†
Visit 4 n (%) 71 (71.00) 71 (71.72) 42 (44.21) 0.0002† 0.0001†
†Chi-square test, Cutoﬀ score for fatigue recovery: CIS score of less than 76 points, 1Comparison of group 1 with the placebo group, 2Comparison of group 2
with the placebo group.4 Evidence-Based Complementary and Alternative Medicine
Table 4: CIS score change.
Group 1 (N = 100) Group 2 (N = 99) Placebo group (N = 95) P value1 P value2
Mean ± SD Mean ± SD Mean ± SD
Baseline (Visit 1) 92.54 ± 11.55 92.43 ± 10.85 91.84 ± 9.73 0.6495∗ 0.6899∗
Visit 3 76.19 ± 12.96 71.49 ± 15.06 76.75 ± 14.60
Visit 4 67.75 ± 13.49 68.02 ± 15.16 74.73 ± 16.45
















Paired t-test, Visit 3 over the baseline = Visit 3, Baseline, Visit 4 over the baseline = Visit 4, Baseline, 1Comparison of group 1 with the
placebo group, 2Comparison of group 2 with the placebo group.
Table 5: Rate of the CIS score reduction.
CIS score Reduction Group 1 (N = 100) Group 2 (N = 99) Placebo (N = 95) P value1 P value2
Yes n (%) 80 (80.00) 76 (76.77) 59 (62.11) 0.0058† 0.0265†
No n (%) 20 (20.00) 23 (23.23) 36 (37.89)
†Chi-square test, Cutoﬀ score for the reduction: CIS score (Baseline-Visit 4) >12 points, 1Comparison of group 1 with the placebo group, 2Comparison of
group 2 with the placebo group.
was conducted to investigate the diﬀerence between the CIS
score change at the baseline and on the fourth week was
found among the subject groups. The chi-square test or
Fisher’s exact test was conducted to investigate the diﬀerence
in the frequency of the subjects who had CIS score changes
of 12 points or higher at the baseline and on the fourth
week was found among the subject groups. As for the safety
assessment of the human placental extract, the chi-square
test or Fisher’s exact test was conducted to investigate the
diﬀerence in the adverse event rate which was found among
the subject groups. All the data were expressed in the form
of the mean ± standard deviation. The analysis results were
considered statistically signiﬁcant if the P value was < 0.05.
3. Results
3.1. Demographic Information and Characteristics of the Sub-
jects. As for the demographic characteristics of the subjects
prior to the study, no statistically signiﬁcant diﬀerences in
all the HADS scores, except for the anxiety score, were
found among the three groups. As a result of the multiple
comparison, using Tukey’s procedure, of the HADS anxiety
scores that signiﬁcantly diﬀered among the subject groups,
a statistically signiﬁcant diﬀerence in the anxiety scores was
found between the experimental groups 1 and 2. Therefore,
it was presumed that the anxiety score diﬀerence would not
aﬀectthecomparisonofgroup1withtheplacebogroup,and
the comparison of group 2 with the placebo group, when
the primary eﬃcacy assessment was analyzed with the CIS
recovery rate (Table 2).
2.97% (3/101 subjects) of Group 1, 6.86% (7/102 sub-
jects) of Group 2, and 2.08% (2/96 subjects) of the Placebo
Group experienced serious life events such as death of
a spouse, divorce or separation, death of close relatives,
injury or disease of less than two weeks, marriage or engage-
ment, school entrance, graduation, transfer, or movement.
No signiﬁcant diﬀerence was found, however, among the
three groups (P value = 0.2544).
3.2. Eﬃcacy Assessment
3.2.1. Fatigue Recovery Rate of the CIS Score. CIS, which is
a tool for fatigue assessment, is used to measure the degree
of fatigue of an individual. A lower CIS score means greater
recovery from fatigue.
At visit 3, the fatigue recovery rate was 51.00% (51/100
subjects) in group 1 and 46.32% (44/95 subjects) in the
placebo group. The fatigue recovery rate was higher in group
1 than in the placebo group, but no statistical diﬀerence
was found between the two groups (P value = 0.5130).
The fatigue recovery rate was higher in group 2 [58.59%
(58/99 subjects)] than in the placebo group, but no statistical
diﬀerence was found between the two groups (P value =
0.0871). At visit 4, the fatigue recovery rate was 71.00%
(71/100 subjects) in group 1 and 44.21% (42/95 subjects)
in the placebo group, which show a statistically signiﬁcant
diﬀerence (P value = 0.0002). The fatigue recovery rate was
higher in group 2 [71.72% (71/99 subjects)] than in the
placebo group, and the rates had a statistically signiﬁcant
diﬀerence (P value = 0.0001) (Table 3).
3.2.2. CIS Score Change. The CIS score measured at visit
4 decreased by 24.79 points (±15.27) in group 1, by 24.79
points (±15.27) in group 2, and by 17.12 points (±17.23) in
theplacebogroupcomparedtotheCISscoresatthebaseline.
The CIS score decreased with statistical signiﬁcance in all the
groups four weeks after the administration of study solution
(P value < 0.0001). The diﬀerence in the CIS score changes
between visit 4 and the baseline was statistically signiﬁcant
between group 1 and the placebo group (P value = 0.0012).
The diﬀerence in the CIS score changes between visit 4 andEvidence-Based Complementary and Alternative Medicine 5
Table 6: Summary of adverse events.
Adverse Event Group 1 N = 101 Group 2 N = 102 Placebo group (N = 96) P value
Adverse event (AE) n (%) 19 (17.92) 16 (15.69) 16 (16.67) 0.9201†
Serious adverse event (SAE) n (%) 1 (0.99) 0 (0.00) 0 (0.00) 0.6599‡
Adverse drug reaction (ADR) n (%) 9 (8.91) 9 (8.82) 4 (4.17) 0.3477†
Withdrawal due to adverse events n (%) 1 (0.99) 2 (1.96) 0 (0.00) 0.7758‡
†Chi-square test, ‡Fisher’s exact test.
the baseline was also statistically signiﬁcant between group
2 and the placebo group (P value = 0.0039). The CIS score
decreased more in the experimental groups 1 and 2 than in
the placebo group (Table 4).
3.2.3. Rate of the CIS Score Reduction. The percentages of
the subjects who had a reduced CIS score of more than
12 points at visit 4 over the baseline (visit 1) were 80.00%
(80/100 subjects) in group 1 and 62.11% (59/9 subjects)
in the placebo group, which show a statistically signiﬁcant
diﬀerence (P value = 0.0058). The percentage of the subjects
who had a reduced CIS score of more than 12 points at
visit 4 over the baseline (visit 1) was 76.77% (76/99 subjects)
in group 2, which shows a statistically signiﬁcant diﬀerence
from that of the placebo group (P value = 0.0265) (Table 5).
3.3. Safety Assessment. No statistically signiﬁcant diﬀerence
in the percentages of the subjects who experienced adverse
events was found among the groups (P value = 0.9201). In
this clinical trial, the percentage of the subjects who experi-
enced serious adverse events was 0.99% (1/101 subjects, 1
case) in group 1. Such percentage turned out to be irrelevant
with the study medication, though. No statistically sign-
iﬁcant diﬀerence in the ADR expressions was found among
the groups (P value = 0.3477) (Table 6).
As for the adverse events that occurred most frequently,
acute pharyngitis and dyspepsia accounted for 2.97% (3
cases) and 2.97% (3 cases), respectively, in group 1. In ad-
dition, nausea accounted for 1.98% (2 cases). On the other
hand,acutepharyngitisaccountedfor3.92%(4cases),which
was the highest frequency in group 2.
In addition, abdominal pain, headache, and urticaria
accounted for 2.94% (3 cases), 1.96% (2 cases), and 1.96%
(2 cases), respectively. Liver enzyme increase accounted for
3.13% (3 cases), which was the highest frequency in the
placebo group. In addition, dyspepsia, acute pharyngitis, up-
per respiratory infection, and myalgia each accounted for
2.08% (2 cases).
4. Discussion
Fatigue, which is an expression of a individual health con-
dition, is a frequently occurring symptom that is associated
with health problems. In most cases, it is temporary and
improved by appropriate rest. If fatigue is severe or has
compounded, however, it may weaken a person’s capability
to lead an ordinary life or cause various diseases, which will
lead to reduced quality of life [9].
It is diﬃcult to conduct a study on fatigue because
fatigue is hard to assess objectively. Although the CIS score is
commonly used in studies on fatigue, it does not resolve the
aforementioned problem. Despite the statistical signiﬁcance
of the results of this study, diﬃculties in clinical studies on
fatigue were seen because the placebo group had a fatigue
recovery rate of more than 40%. The results of this study
showed a relatively higher placebo eﬀect than the results of
otherstudies.Thisislikelytobeduetothefollowingreasons.
First, the subjects could have participated in this study with
high expectations from the “placental nutrients” that are
sold at high prices. Second, the placebo used in this study
had a sweet taste that was similar to that of the ergogenic
drinks that are sold in the market, which could have made
the subjects feel temporary recovery from psychological
fatigue.
This study has another disadvantage: the short duration
of the administration period. Considering that the eﬀect
of the human placental extract does not emanate from its
direct administration but from its interaction with cytokine,
hormones, or other unknown ingredients in the extract, it
is likely that the four-week period was insuﬃcient. This was
also conﬁrmed by the study result that the fatigue recovery
eﬀect was higher on the fourth week than on the second
week.
The human placental extract is preferred, as it is known
to be free from adverse events. As shown in this study, no
serious adverse event was found in the human placental
extract, and the frequency of its adverse events was also
low. Thorough management and regulation of raw material
collection and manufacturing are required, however, as the
human placental extract is extracted from body tissues.
Previous clinical studies on the human placental extract
were mainly conducted to investigate hepatic dysfunction
[10], menopausal disorder [11], and skin whitening [5, 6].
This study is valuable as a multicenter, double-blind study
that ﬁrst assessed the eﬃcacy and safety of the oral human
placental extract on fatigue. Furthermore, the results of this
study are valuable because they can provide more treatment
options to fatigue patients in the current situation wherein
only a few eﬀective treatments for fatigue are available.
5. Conclusions
T h eo r a lh u m a np l a c e n t a le x t r a c tw a se ﬀective in the
improvement of fatigue. The adverse event frequency in
the experimental groups was similar to that in the placebo
group.6 Evidence-Based Complementary and Alternative Medicine
It is likely that more comprehensive results that can
address the limitations of this study can be obtained if
a study that has a suﬃcient period of study process and
precisely classiﬁes the subjects’ ages and degrees of fatigue is
conducted.
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